Notable side effects of<unk>  seen in clinical trials have included gynecomastia, breast pain/tenderness, fatigue, diarrhea, hot flashes, headache, sexual dysfunction, and, less commonly, seizures. Other "common" side effects reported in clinical trials have included neutropenia, visual hallucinations, anxiety, cognitive disorder, memory impairment, hypertension, dry skin, and pruritus (itching).<unk>  monotherapy is regarded as having a moderate negative effect on sexual function and activity, significantly less than that of GnRH analogues but similar to that of other NSAAs such as bicalutamide. Central adverse effects Seizures have occurred in approximately 1% of patients treated with<unk>  in clinical trials. This is thought to be due to<unk>  crossing the blood–brain barrier and exerting off-target binding to and inhibition of the GABAA receptor in the central nervous system (it has been found to inhibit the GABAA receptor in vitro ( = 3.6 μM) and induces convulsions in animals at high doses). In addition to seizures, other potentially GABAA receptor-related side effects observed with<unk>  treatment in clinical trials have included anxiety, insomnia, vertigo, paresthesia, and headache. Due to its ability to lower the seizure threshold, patients with known seizure disorders or brain injury should be closely monitored during<unk>  treatment. NSAA-induced seizures are responsive to benzodiazepine treatment, and it has been suggested that GABAA receptor inhibition by<unk>  could be treated with these drugs. In dose-ranging studies, severe fatigue was observed with<unk>  at doses of 240 mg/day and above. Rare adverse reactions There is a single case report of posterior reversible encephalopathy syndrome (PRES) with<unk>  treatment. The mechanism of action of the side effect is unknown, but it was proposed to a consequence of inhibition of the GABAA receptor by<unk> .
Enzalutamide
Bicalutamide
Flutamide
Apalutamide
Nilutamide
Topilutamide
Darolutamide
Tamoxifen